ClinicalTrials.gg
TerminatedNCT01315496Updated Apr 30, 2013

GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock

A Phase 3 interventional study of Immunoglobulin G in Severe Sepsis and Septic Shock, sponsored by Green Cross Corporation. Terminated at 17 sites in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-04-30.

Primary conditionShock, SepticRegistry: SepsisReclassifiedWhy we changed it
Registry
Sepsis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Shock, Septic
Why
  1. The study's listed conditions name Shock, Septic, a narrower term within Sepsis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Green Cross Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
214
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Shock, Septic with a site in Korea, Republic of — 2 open to participants now, 2 under way, none of them phase 3. Shock, Septic · Korea, Republic of.

Planned enrollment
5th of 10
214 · median 165
Started
2009
with 1 other
Phase 3
3 of 11
none open now
Registered
4th of 11
by date
Lead sponsor
1 of 11
Green Cross Corporation

Among the 11 studies in Shock, Septic with a site in Korea, Republic of, this one is the 5th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2009, is one of 3 in phase 3, and was the 4th registered.

Shock, Septic

1,079 studies on the registry are indexed under Shock, Septic; 233 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

2 of the 11 studies in Shock, Septic with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 102 (74%) set no upper age limit and 19 (14%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Shock, Septic with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study is to determine whether the intravenous application of 'Ⅳ-Globulin S inj. (Human Immunoglobulin G)' can reduce mortality in patients with severe sepsis or septic shock.

Read the detailed description

A Placebo-controlled, Randomized, Double-blind, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Administration of 'IV-Globulin S inj.(Human Immunoglobulin G)' as an Adjuvant Therapy in Adult Subjects with Community-Acquired Severe Sepsis or Septic Shock.

03

Conditions studied

  • Severe Sepsis
  • Septic Shock

Browse trials for

Keywords

  • Human Immunoglobulin G
  • Sepsis
  • Septic shock
04

In context

Shock, Septic Reclassified

1,079 studies on the registry are indexed under Shock, Septic; 233 are open to participants now.

This study's planned enrollment of 214 is above the median of 79 across 636 interventional studies indexed under Shock, Septic.

Browse Shock, Septic studies →

Lead sponsor

Green Cross Corporation is the lead sponsor of 63 studies on the registry; 1 is open to participants now.

Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with severe sepsis or septic shock, if all of the following criteria is satisfied.

    1. Age ≥ 18 years
    2. Proved or suspected infection in at least one site
  • pneumonia
  • urinary tract infection
  • intra-abdominal infection
  • primary bloodstream infection
  • skin and soft tissue infection 3. Three or more of the following
  • a core temperature ≥ 38° C or ≤ 36° C
  • a heart rate ≥ 90 beats/min
  • a respiratory rate ≥ 20 breaths/min or PaCO2 ≤ 32 mmHg or use of mechanical ventilation for an acute process
  • a white blood cell count ≥ 12000/mm3 or ≤ 4000/ mm3 or immature neutrophils > 10% 4. Acute organ failure in one or more of the following
  • kidney
  • respiratory system
  • blood system
  • metabolic system
  • circulatory system 5. APACHE score ≥ 20 and ≤ 29 6. Patient can treatment with GCIV in ICU within at least 48 hours 7.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breast-feeding women
  2. a weight > 100kg
  3. discharged from the hospital at least 14 days prior to new admission
  4. Transferred from another hospital staying more than 48 hours
  5. allergy or shock of IVIG
  6. Treated with IVIG within the 12 weeks immediately preceding enrolment in this study
  7. IgA deficiency
  8. Hypernatremia or hyperhydration
  9. Proved or suspected or AIDS patients(CD4+ \<200mL)
  10. Current participation in any study within the last 4 weeks
  11. Do not resuscitate (DNR) status
  12. Patient's death is considered imminent due to coexisting disease
  13. physicians decision to exclude patients from this protocol
  14. patients
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
214 participants (estimated)

Study arms

  • Experimental
    Imunoglobulin G

    The enrolled patients will be randomized to receive supplementation of IVIG in ICU within 48 hours after hospital arrival admission for 3 consecutive days.

    Drug: Immunoglobulin G

  • Placebo comparator
    Placebo control

    The enrolled patients will be randomized to receive supplementation of placebo (0.9% NaCl) in ICU within 48 hours after hospital arrival admission for 3 consecutive days.

    Drug: Immunoglobulin G

Interventions

07

What researchers measure

Primary outcomes

  1. All cause mortality

    Time frame: 28th day

Secondary outcomes

  1. All cause mortality

    Time frame: 7th day

  2. Course of SOFA subscores

    Time frame: 5 Times: D-1, D1, D3, D5, D7

  3. Laboratory Test

    sputum culture test, CBC, blood chemistry, blood coagulation test, CRP, ABGA

    Time frame: 7th Day

  4. Duration of ICU and general ward admission

    Time frame: 28 days

08

Study locations

17 sites
  • Korea University Ansan Hospital
    Ansan, Korea, Republic of
  • Hallym University Sacred Heart Hospital
    Anyang, Korea, Republic of
  • Chungbuk National University Hospital
    Cheongju, Korea, Republic of
  • Gachon University Gil Hospital
    Incheon, Korea, Republic of
  • Gyrongsang National University Hospital
    Jinju-si, Gyeongsangnam-do,, Korea, Republic of
  • Asan Medical Center
    Seoul, Korea, Republic of
  • Ewha Womans University Mokdong Hospital
    Seoul, Korea, Republic of
  • Kangdong Sacred Heart Hospital
    Seoul, Korea, Republic of
  • Kangnam Sacred Heart Hospital
    Seoul, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, Korea, Republic of
  • Korea University Guro Hospital
    Seoul, Korea, Republic of
  • Samsung Medical Center
    Seoul, Korea, Republic of
  • Seoul Medical Center
    Seoul, Korea, Republic of
  • Severance Hospital
    Seoul, Korea, Republic of
  • The Catholic of Korea Yeouido ST. Mary's Hospital
    Seoul, Korea, Republic of
  • Ajuo University Hospital
    Suwon, Korea, Republic of
  • Wonju Christian Hospital
    Wonju, Korea, Republic of
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2011
First posted
Mar 15, 2011
Start
Oct 2009
Primary completionEst.
Dec 2013
CompletionEst.
Dec 2013
Last update
Apr 30, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01315496
Collaborators
Symyoo
Responsible party
Sponsor
First posted
Mar 15, 2011
Start date
Oct 2009
Primary completion
Dec 2013 (estimated)
Completion
Dec 2013 (estimated)
Last update
Apr 30, 2013

Study contacts

Min Ja Kim, Professor
principal investigator · Korea University Anam Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulin G

Start the discussion